The historical rank and industry rank for Acura Pharmaceuticals's Pretax Margin % or its related term are showing as below:
STU:HD4B's Pretax Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.295 * Ranked among companies with meaningful Pretax Margin % only.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Acura Pharmaceuticals Pretax Margin % Related Terms
Acura Pharmaceuticals Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Acura Pharmaceuticals's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:HD4B vs VFRM, THCT, CBGL: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Acura Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acura Pharmaceuticals Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Acura Pharmaceuticals's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Acura Pharmaceuticals's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acura Pharmaceuticals (STU:HD4B) has a Pretax Margin % of 81.25% as of Dec. 2021. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Acura Pharmaceuticals and its competitors.
Is Acura Pharmaceuticals' Pretax Margin % too high?
Acura Pharmaceuticals' current Pretax Margin % is 81.25%. The Drug Manufacturers industry median Pretax Margin % is 7.30. Acura Pharmaceuticals' value of 81.25% is 1013.8% above this industry median. Overall, Acura Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Acura Pharmaceuticals' Pretax Margin % compare to VFRM and THCT?
Acura Pharmaceuticals' Pretax Margin % of 81.25% can be compared against companies in the Drug Manufacturers industry. The industry median Pretax Margin % is 7.30. Acura Pharmaceuticals' value of 81.25% is 1013.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acura Pharmaceuticals's current Pretax Margin % of 81.25% is 1013.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Acura Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acura Pharmaceuticals's current Pretax Margin % is 81.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acura Pharmaceuticals stock overvalued right now?
Acura Pharmaceuticals (STU:HD4B) has a current Pretax Margin % of 81.25%. The current Pretax Margin % is 81.25% and 1013.8% above the Drug Manufacturers industry median of 7.30. Acura Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Acura Pharmaceuticals (STU:HD4B), the current Pretax Margin % is 81.25% as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acura Pharmaceuticals Inc is a drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. It has discovered and developed three proprietary platform technologies which can be used to develop multiple products. Its Limitx Technology is being developed to minimize the risk of overdose, its Aversion Technology is intended to address methods of abuse associated with opioid analgesics while its Impede Technology is directed at minimizing the extraction and conversion of pseudoephedrine, or PSE, into methamphetamine. It operates in single segment being the research, development and commercialization of technologies and products intended to address safe use of medications.
16GF Score
Get the complete analysis for STU:HD4B
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:HD4B has been successfully added to your 
